2019
Long‐term safety of adalimumab in adult patients with plaque psoriasis
Leonardi C, Papp K, Strober B, Thaçi D, Warren R, Tyring S, Arikan D, Karunaratne M, Valdecantos W. Long‐term safety of adalimumab in adult patients with plaque psoriasis. British Journal Of Dermatology 2019, 180: e13-e13. DOI: 10.1111/bjd.17366.Peer-Reviewed Original ResearchNon-melanoma skin cancerPatient yearsLong-term safetyIncidence of NMSCTumor necrosis factor alphaMost common AEsNew safety signalsUpper respiratory infectionIncidence of malignancyAnalysis of patientsNumber of patientsNecrosis factor alphaDifferent clinical trialsCommon AEsPlaque psoriasisAdult patientsAdverse eventsRespiratory infectionsOpportunistic infectionsSerious infectionsClinical trialsIncidence rateSafety signalsFactor alphaAdalimumab
2017
A Telemonitoring Service Supporting Preterm Newborns Care in a Neonatal Intensive Care Unit
Losiouk E, Lanzola G, Galderisi A, Trevisanuto D, Steil G, Facchinetti A, Cobelli C. A Telemonitoring Service Supporting Preterm Newborns Care in a Neonatal Intensive Care Unit. 2017, 1-6. DOI: 10.1109/rtsi.2017.8065890.Peer-Reviewed Original ResearchNeonatal intensive care unitIntensive care unitCare unitPreterm newbornsLow birth weight infantsBirth weight infantsGlucose infusion rateDifferent clinical trialsHealth care staffContinuous glucose monitoringWeight infantsHeel prickNewborn careClinical benefitUniversity HospitalClinical trialsInfusion rateCare staffArterial samplingGlucose monitoringWard roomsGlucose dataGlucose concentrationPatientsNewborns
2009
p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials.
Lehmann-Che J, André F, Desmedt C, Giacchetti S, Sotiriou C, Turpin E, Espié M, Marty M, Piccart M, Pusztai L, De Thé H. p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials. Cancer Research 2009, 69: 6064. DOI: 10.1158/0008-5472.sabcs-6064.Peer-Reviewed Original ResearchPathologic complete responseAnthracycline-based chemotherapyPCR rateWild-type tumorsP53 wild-type tumorsP53 mutationsType tumorsPredictive valueAnthracycline-containing chemotherapyBreast cancer patientsDifferent clinical trialsDifferent clinical studiesP53 mutant tumorsInvasive tumor cellsDose intensityComplete responseLymph nodesCancer patientsNegative cancersClinical trialsBreast cancerClinical studiesEstrogen receptorTOP trialPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply